Meet Zerion Pharma’s management and regulatory team – CEO Ole Wiborg, CFO Jakob Dynnes Hansen, and Mónica González VP Regulatory Affairs. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome® technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

It is an online event taking place on 20 February, 14:30 - 15:00.  

 Register by clicking on the link: https://hcandersencapital.dk/event/https-www-inderes-dk-videos-zerion-pharma-regulatory-environment-and-strategic-partnerships/

The company aims to make a real difference in health care with its Dispersome® technology in relation to the formulation of new and existing drugs. Poor drug solubility is one of the main reasons for drug development failure. ZERION has a solution - Dispersome® - a technology that increases the chance of success for new drug development, allows for improvement of existing drugs enabling more new drugs to reach the market and leads to improved treatment of patients as well as reduced toxic waste. The Dispersome® technology makes it possible to reduce the number of active drugs by up to 75%.